The ruling on Friday from a U.S. federal appeals court in New York reverses a lower court decision and backs the company's right to patenht two "isolated" human genes - BRCA1 and BRCA 2 - that account for most inherited forms of breast and ovarian cancers.
No comments:
Post a Comment